{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Free Realtime Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "SEK", "marketState": "REGULAR", "regularMarketChangePercent": -0.18116356, "regularMarketPrice": 27.55, "exchange": "STO", "shortName": "BioInvent International AB", "longName": "BioInvent International AB (publ)", "messageBoardId": "finmb_139682", "exchangeTimezoneName": "Europe/Stockholm", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "se_market", "esgPopulated": false, "regularMarketTime": 1684143012, "earningsTimestamp": 1682488800, "earningsTimestampStart": 1682488800, "earningsTimestampEnd": 1682488800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.62, "epsForward": -3.93, "sharesOutstanding": 65804400, "bookValue": 23.765, "fiftyDayAverage": 28.46, "fiftyDayAverageChange": -0.90999985, "fiftyDayAverageChangePercent": -0.031974696, "twoHundredDayAverage": 36.16075, "twoHundredDayAverageChange": -8.610752, "twoHundredDayAverageChangePercent": -0.23812425, "marketCap": 1862173184, "forwardPE": -7.0101776, "priceToBook": 1.1592678, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 992329200000, "priceHint": 2, "regularMarketChange": -0.050001144, "regularMarketDayHigh": 28.05, "regularMarketDayRange": "27.35 - 28.05", "regularMarketDayLow": 27.35, "regularMarketVolume": 2832, "regularMarketPreviousClose": 27.6, "bid": 27.5, "ask": 27.85, "bidSize": 0, "askSize": 0, "fullExchangeName": "Stockholm", "financialCurrency": "SEK", "regularMarketOpen": 27.4, "averageDailyVolume3Month": 20774, "averageDailyVolume10Day": 15363, "fiftyTwoWeekLowChange": 1.75, "fiftyTwoWeekLowChangePercent": 0.06782946, "fiftyTwoWeekRange": "25.8 - 51.1", "fiftyTwoWeekHighChange": -23.55, "fiftyTwoWeekHighChangePercent": -0.46086106, "fiftyTwoWeekLow": 25.8, "fiftyTwoWeekHigh": 51.1, "symbol": "BINV.ST"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "The Gamma Building", "address2": "Ideongatan 1", "city": "Lund", "zip": "223 70", "country": "Sweden", "phone": "46 4 62 86 85 50", "website": "https://www.bioinvent.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.", "fullTimeEmployees": 102, "companyOfficers": [{"maxAge": 1, "name": "Dr. Martin  Welschof Ph.D.", "age": 61, "title": "Pres & CEO", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 5061000, "fmt": "5.06M", "longFmt": "5,061,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Stefan  Ericsson M.B.A.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Marie  Moores M.Sc., R.G.N.", "title": "Chief Operating Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kristoffer Rudenholm Hansson", "age": 48, "title": "Sr. VP of Technical Operations", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bj\u00f6rn  Frend\u00e9us", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cecilia  Hofvander", "age": 55, "title": "Sr. Director of Investor Relations", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Andres  McAllister", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1956, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Ingrid  Teige", "title": "Head of Preclinical Research", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sylvie  Ryckebusch", "title": "Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 2, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 5, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}